Antitumor effect of histone deacetylase inhibitors

doi:10.3760/cma.j.issn.1673-422X.2017.10.008

Abstract

Abstract: Histone deacetylase (HDAC) is a kind of protease, which plays an important role in the structural modification of chromosomes and the regulation of gene expression. Its excessive expression in cancer cells causes acetylation imbalance, which is closely related to the occurrence of tumor. The high efficiency and low toxicity of histone deacetylase inhibitor (HDACi) has been widely recognized as antitumor drug with the deepening of the study in epigenetics. It is expected to bring more breakthroughs in the treatment of tumor.

Key words: Epigenesis, genetic, Neoplasms, Histone deacetylase inhibitors

Xiao Sa, Li Ling, Zhang Mingzhi. Antitumor effect of histone deacetylase inhibitors[J]. Journal of International Oncology, 2017, 44(10): 754-757.

References

［1］ Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis［J］. J Mol Biol, 2004, 338(1): 1731. DOI: 10.1016/j.jmb.2004.02.006. ［2］ Deacetylases H. Characterization of the classical HDAC family［J］. Biochem J, 2003, 370(Pt 3): 737749. ［3］ Lakshmaiah KC, Jacob LA, Aparna S, et al. Epigenetic therapy of cancer with histone deacetylase inhibitors［J］. J Cancer Res Ther, 2014, 10(3): 469478. DOI: 10.4103/09731482.137937. ［4］ Koeneke E, Witt O, Oehme I. HDAC family members intertwined in the regulation of autophagy: a druggable vulnerability in aggressive tumor entities［J］. Cells, 2015, 4(2): 135168. DOI: 10.3390/cells4020135. ［5］ Olsen EA, Kim YH, Kuzel TM, et al. Phase Ⅱb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous Tcell lymphoma［J］. J Clin Oncol, 2007, 25(21): 31093115. DOI: 10.1200/JCO.2006.10.2434. ［6］ Damaskos C, Karatzas T, Nikolidakis L, et al. Inhibitors: current evidence for therapeutic activities in pancreatic cancer［J］. Anticancer Res, 2015, 35(6): 31293135. ［7］ Takashina T, Kinoshita I, Kikuchi J, et al. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for nonsmallcell lung cancer cells［J］. Cancer Sci, 2016, 107(7): 955962. DOI: 10.1111/cas.12957. ［8］ Shin DY, Kim SJ, Yoon DH, et al. Results of a phase Ⅱ study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis［J］. Cancer Chemother Pharmacol, 2016, 77(4): 865873. DOI: 10.1007/s002800163005y. ［9］ Pili R, Liu G, Chintala S, et al. Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clearcell renal cell carcinoma: a multicentre, singlearm phase Ⅰ/Ⅱ clinical trial［J］. Br J Cancer, 2017, 116(7): 874883. DOI: 10.1038/bjc.2017.33. ［10］ Pera B, Tang T, Marullo R, et al. Combinatorial epigenetic therapy in diffuse large B cell lymphoma preclinical models and patients［J］. Clin Epigenetics, 2016, 8: 79. DOI: 10.1186/s131480160245y. ［11］ Holkova B, Kmieciak M, Bose P, et al. Phase 1 trial of carfilzomib (PR171) in combination with vorinostat (SAHA) in patients with relapsed or refractory Bcell lymphomas［J］. Leuk Lymphoma, 2016, 57(3): 635643. DOI: 10.3109/10428194.2015.1075019. ［12］ Angelika Ihle M, MerkelbachBruse S, Hartmann W, et al. HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat［J］. J Pathol Clin Res, 2016, 2(2): 5971. DOI: 10.1002/cjp2.35. ［13］ Gu R, Liu T, Zhu X, et al. Development and validation of a sensitive HPLCMS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application［J］. J Chromatogr B Analyt Technol Biomed Life Sci, 2015, 1000: 181186. DOI: 10.1016/j.jchromb.2015.07.001. ［14］ Hu X, Wang L, Lin L, et al. A phase Ⅰ trial of an oral subtypeselective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced nonsmall cell lung cancer［J］. Chin J Cancer Res, 2016, 28(4): 444451. DOI: 10.21147/j.issn.10009604.2016.04.08. ［15］ Zhao S, Guo J, Zhao Y, et al. Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2/STAT3 signaling［J］. Am J Transl Res, 2016, 8(7): 31693178. ［16］ Liu L, Qiu S, Liu Y, et al. Chidamide and 5flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice［J］. Neoplasma, 2016, 63(2): 193200. DOI: 10.4149/203_150422N214. ［17］ Lee HZ, Kwitkowski VE, Del Valle PL, et al. FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral Tcell lymphoma［J］. Clin Cancer Res, 2015, 21(12): 26662670. DOI: 10.1158/10780432.CCR143119. ［18］ O′Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral Tcell lymphoma: results of the pivotal phase Ⅱ BELIEF (CLN19) study. J Clin Oncol, 2015, 33(23): 24922499. DOI: 10.1200/JCO.2014.59.2782. ［19］ O′connor OA, Zullo K, Marchi E, et al. Targeting epigenetic operations with HDAC inhibitor and hypomethylating drugs in combination exhibit synergy in preclinical and clinical experiences in drug resistant Tcell lymphoma (TCL): a translational focus on doublet development［J］. Blood, 2015, 126(23): 109120. ［20］ Havas AP, Rodrigues KB, Bhakta A, et al. Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma［J］. Cancer Biol Ther, 2016, 17(12): 12401252. DOI: 10.1080/15384047.2016.1250046. ［21］ To KK, Tong WS, Fu LW. Reversal of Platinum drug resistance by the histone deacetylase inhibitor belinostat［J］. Lung Cancer, 2017, 103: 5865. DOI: 10.1016/j.lungcan.2016.11.019. ［22］ SanMiguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, doubleblind phase 3 trial［J］. Lancet Oncol, 2014, 15(11): 11951206. DOI: 10.1016/S14702045(14)704401. ［23］ Richardson PG, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment［J］. Blood, 2016, 127(6): 713721. DOI: 10.1182/blood201509665018. ［24］ Shi W, Palmer JD, WernerWasik M, et al. Phase Ⅰ trial of panobinostat and fractionated stereotactic reirradiation therapy for recurrent high grade gliomas［J］. J Neurooncol, 2016, 127(3): 535539. DOI: 10.1007/s1106001620593. ［25］ Tan WW, Allred JB, MorenoAspitia A, et al. Phase Ⅰ study of panobinostat (LBH589) and letrozole in postmenopausal metastatic breast cancer patients［J］. Clin Breast Cancer, 2016, 16(2): 8286. DOI: 10.1016/j.clbc.2015.11.003. ［26］ Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, openlabel, phase Ⅱ study of romidepsin in relapsed or refractory peripheral Tcell lymphoma after prior systemic therapy［J］. J Clin Oncol, 2012, 30(6): 631636. DOI: 10.1200/JCO.2011.37.4223. ［27］ Foss F, Horwitz S, Pro B, et al. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial［J］. J Hematol Oncol, 2016, 9(1): 22. DOI: 10.1186/s1304501602438. ［28］ Pellegrini C, Dodero A, Chiappella A, et al. A phase Ⅱ study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral Tcell lymphoma patients［J］. J Hematol Oncol, 2016, 9(1): 38. DOI: 10.1186/s1304501602661.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.